Oritavancin (phosphate) (Synonyms: LY 333328) |
| Katalog-Nr.GC44515 |
Oritavancin (Phosphat) (LY333328-Diphosphat) ist ein oral wirksames Glykopeptid-Antibiotikum mit AktivitÄt gegen grampositive Organismen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 192564-14-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Oritavancin is a semisynthetic glycopeptide antibiotic that inhibits the growth of Gram-positive bacteria. It inhibits transglycosylation and transpeptidation in the bacterial cell wall to disrupt membrane integrity. Oritavancin inhibits the growth of clinical isolates from skin and soft-tissue infections, including methicillin-resistant and -susceptible S. aureus (MRSA, MSSA), vancomycin-resistant and -susceptible E. faecium (VREF, VSRF), as well as other staphylococci, streptococci, and enterococci (MIC90s = ≤0.008-0.5 mg/L). Oritavancin inhibits growth of S. aureus in a neutropenic-mouse thigh model of infection (ED50 = 0.95 mg/kg for a single dose). It improves survival in a mouse inhalation model of B. anthracis Ames anthrax when administered prophylactically pre- and postexposure and when administered post symptom development. Formulations containing oritavancin have been used to treat bacterial skin infections.
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *